Therapeutic Dose Monitoring of Busulfan is Associated with a Reduction in Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Non-Hodgkin lymphoma (NHL) is typically sensitive to conventional doses of chemotherapy but many patients do not respond to front-line treatment or subsequently relapse after achieving remission. For medically-fit patients with relapsed/refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), subsequent treatment with high dose chemotherapy and autologous hematopoietic stem cell transplantation (ASCT) is often indicated [1 –4]. ASCT is also performed as consolidation treatment for patients with mantle cell lymphoma (MCL) and peripheral T-cell lymphoma (PTCL) and is associated with favorable progression-free survival (PFS) [5–7].

Source: Biology of Blood and Marrow Transplantation - October 10, 2019 Category: Hematology Authors: Brian T. Hill, Lisa A. Rybicki, Theresa A. Urban, Mariana Lucena, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Ronald M. Sobecks, Brad Pohlman, Brian Bolwell, Matt E. Kalaycio, Betty K. Hamilton, Edward A. Copelan, Navneet S. Majhail Source Type: research